Compare IMSR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMSR | GERN |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | 74 | 258 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 901.5M | 808.3M |
| IPO Year | N/A | N/A |
| Metric | IMSR | GERN |
|---|---|---|
| Price | $6.73 | $1.32 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 3.0M | ★ 13.0M |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.33 | $1.04 |
| 52 Week High | $16.38 | $2.01 |
| Indicator | IMSR | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 40.77 | 50.84 |
| Support Level | $5.82 | $1.23 |
| Resistance Level | $6.85 | $1.30 |
| Average True Range (ATR) | 0.65 | 0.08 |
| MACD | -0.14 | 0.03 |
| Stochastic Oscillator | 9.56 | 52.56 |
Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.